title: Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study.
authors: Rheumatology Department, Hopsital Clinic de Barcelona, Barcelona, Spain.
authors: Raimon
authors: R
authors: Sanmarti
authors: Rheumatology Department, Hopsital Clinic de Barcelona, Barcelona, Spain.
authors: Jose
authors: J
authors: Inciarte-Mundo
authors: Rheumatology Department, Hopsital Clinic de Barcelona, Barcelona, Spain.
authors: Paula
authors: P
authors: Estrada-Alarcon
authors: Rheumatology Department, Hopsital Clinic de Barcelona, Barcelona, Spain.
authors: Maria
authors: M
authors: Garcia-Manrique
authors: Rheumatology Department, Hopsital Clinic de Barcelona, Barcelona, Spain.
authors: Javier
authors: J
authors: Narvaez
authors: Rheumatology Department, Hopsital Clinic de Barcelona, Barcelona, Spain.
authors: Jesus
authors: J
authors: Rodriguez-Moreno
authors: Rheumatology Department, Hopsital Clinic de Barcelona, Barcelona, Spain.
authors: Antoni
authors: A
authors: Gomez-Centeno
authors: Rheumatology Department, Hopsital Clinic de Barcelona, Barcelona, Spain.
authors: Mariona
authors: M
authors: Pascal
authors: Rheumatology Department, Hopsital Clinic de Barcelona, Barcelona, Spain.
authors: Jordi
authors: J
authors: Yagüe
mesh_terms: D000906:Antibodies / Q000097:blood*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000097:blood* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
chemical_list: D000906:Antibodies; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor
keywords: DAS28; Rheumatoid Arthritis; Treatment